These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33714231)

  • 1. Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017.
    Langenbruch A; Mohr N; Kirsten N; Reich K; von Kiedrowski R; Strömer K; Mrowietz U; Augustin M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1536-1542. PubMed ID: 33714231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of psoriasis care in Germany: results of the national health care study "PsoHealth3".
    Langenbruch A; Radtke MA; Jacobi A; Purwins S; Haack K; Reich K; Stroemer K; Mrowietz U; Augustin M
    Arch Dermatol Res; 2016 Aug; 308(6):401-8. PubMed ID: 27206971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.
    Augustin M; Reich K; Reich C; Purwins S; Jeff Rustenbach S; Schäfer I; Radtke M
    J Dtsch Dermatol Ges; 2008 Aug; 6(8):640-5. PubMed ID: 18801145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management.
    Augustin M; Langenbruch A; Gutknecht M; Reich K; Körber A; Maaßen D; Mrowietz U; Thaçi D; von Kiedrowski R; Radtke MA
    Br J Dermatol; 2018 Dec; 179(6):1385-1391. PubMed ID: 30334253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
    Radtke MA; Schäfer I; Blome C; Augustin M
    Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators.
    Radtke MA; Reich K; Blome C; Kopp I; Rustenbach SJ; Schäfer I; Augustin M
    Dermatology; 2009; 219(1):54-8. PubMed ID: 19420901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
    Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.
    Balogh O; Brodszky V; Gulácsi L; Herédi E; Herszényi K; Jókai H; Kárpáti S; Baji P; Remenyik É; Szegedi A; Holló P
    Eur J Health Econ; 2014 May; 15 Suppl 1():S101-9. PubMed ID: 24832841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
    Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
    Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.
    Augustin M; Krüger K; Radtke MA; Schwippl I; Reich K
    Dermatology; 2008; 216(4):366-72. PubMed ID: 18319601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study).
    Youn SW; Lee JH; Yu DY; Kim Y; Kim BS; Seo SJ; Choe YB; Yun SK; Park J; Kim NI; Choi CW; Youn JI; Lee SJ; Lee MG; Kim KJ; Park CJ; Ro YS; Song HJ; Shin BS; Ahn SK; Lee JY; Won YH; Jang MS; Kim KH; Kim MH; Kim TY; Choi JH
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1499-1506. PubMed ID: 29430733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial.
    Schmitt J; Wozel G; Garzarolli M; Viehweg A; Bauer M; Leopold K
    Acta Derm Venereol; 2014 Mar; 94(2):192-7. PubMed ID: 23995849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H; Sato N; Yoshinari T; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.